73 research outputs found

    XBP-1 specifically promotes IgM synthesis and secretion, but is dispensable for degradation of glycoproteins in primary B cells

    Get PDF
    Differentiation of B cells into plasma cells requires X-box binding protein–1 (XBP-1). In the absence of XBP-1, B cells develop normally, but very little immunoglobulin is secreted. XBP-1 controls the expression of a large set of genes whose products participate in expansion of the endoplasmic reticulum (ER) and in protein trafficking. We define a new role for XBP-1 in exerting selective translational control over high and sustained levels of immunoglobulin M (IgM) synthesis. XBP-1−/− and XBP-1+/+ primary B cells synthesize IgM at comparable levels at the onset of stimulation with lipopolysaccharide or CpG. However, later there is a profound depression in synthesis of IgM in XBP-1−/− B cells, notwithstanding similar levels of μmRNA. In marked contrast, lack of XBP-1 does not affect synthesis and trafficking of other glycoproteins, or of immunoglobulin light chains. Contrary to expectation, degradation of proteins from the ER, using TCRα or US11-mediated degradation of class I major histocompatibility complex molecules as substrates, is normal in XBP-1−/− B cells. Furthermore, degradation of membrane μ was unaffected by enforced expression of XBP-1. We conclude that in primary B cells, the XBP-1 pathway promotes synthesis and secretion of IgM, but does not seem to be involved in the degradation of ER proteins, including that of μ chains themselves

    The second-generation antipsychotic drug aripiprazole modulates the serotonergic system in pancreatic islets and induces beta cell dysfunction in female mice

    Get PDF
    [Aims/hypothesis]: Second-generation antipsychotic (SGA) drugs have been associated with the development of type 2 diabetes and the metabolic syndrome in patients with schizophrenia. In this study, we aimed to investigate the effects of two different SGA drugs, olanzapine and aripiprazole, on metabolic state and islet function and plasticity. [Methods]: We analysed the functional adaptation of beta cells in 12-week-old B6;129 female mice fed an olanzapine- or aripiprazole-supplemented diet (5.5–6.0 mg kg−1 day−1) for 6 months. Glucose and insulin tolerance tests, in vivo glucose-stimulated insulin secretion and indirect calorimetry were performed at the end of the study. The effects of SGAs on beta cell plasticity and islet serotonin levels were assessed by transcriptomic analysis and immunofluorescence. Insulin secretion was assessed by static incubations and Ca2+ fluxes by imaging techniques. [Results]: Treatment of female mice with olanzapine or aripiprazole for 6 months induced weight gain (p<0.01 and p<0.05, respectively), glucose intolerance (p<0.01) and impaired insulin secretion (p<0.05) vs mice fed a control chow diet. Aripiprazole, but not olanzapine, induced serotonin production in beta cells vs controls, likely by increasing tryptophan hydroxylase 1 (TPH1) expression, and inhibited Ca2+ flux. Of note, aripiprazole increased beta cell size (p<0.05) and mass (p<0.01) vs mice fed a control chow diet, along with activation of mechanistic target of rapamycin complex 1 (mTORC1)/S6 signalling, without preventing beta cell dysfunction. [Conclusions/interpretation]: Both SGAs induced weight gain and beta cell dysfunction, leading to glucose intolerance; however, aripiprazole had a more potent effect in terms of metabolic alterations, which was likely a result of its ability to modulate the serotonergic system. The deleterious metabolic effects of SGAs on islet function should be considered while treating patients as these drugs may increase the risk for development of the metabolic syndrome and diabetes.This work was funded by H2020 Marie Sklodowska-Curie ITN-TREATMENT (Grant Agreement 721236, European Commission). We also acknowledge grants RTI2018-094052-B-100/ AEI/10.13039/501100011033 (Ministerio de Ciencia e Innovación y Fondo Europeo de Desarrollo Regional [FEDER]) and S2017/BMD-3684 (Comunidad de Madrid, Spain), and grants from Fundación Ramón Areces (Spain) and CIBERDEM (ISCIII, Spain)

    Enhanced Transferrin Receptor Expression by Proinflammatory Cytokines in Enterocytes as a Means for Local Delivery of Drugs to Inflamed Gut Mucosa

    Get PDF
    Therapeutic intervention in inflammatory bowel diseases (IBDs) is often associated with adverse effects related to drug distribution into non-diseased tissues, a situation which attracts a rational design of a targeted treatment confined to the inflamed mucosa. Upon activation of immune cells, transferrin receptor (TfR) expression increases at their surface. Because TfR is expressed in all cell types we hypothesized that its cell surface levels are regulated also in enterocytes. We, therefore, compared TfR expression in healthy and inflamed human colonic mucosa, as well as healthy and inflamed colonic mucosa of the DNBS-induced rat model. TfR expression was elevated in the colonic mucosa of IBD patients in both the basolateral and apical membranes of the enterocytes. Increased TfR expression was also observed in colonocytes of the induced colitis rats. To explore the underlying mechanism CaCo-2 cells were treated with various proinflammatory cytokines, which increased both TfR expression and transferrin cellular uptake in a mechanism that did not involve hyper proliferation. These findings were then exploited for the design of targetable carrier towards inflamed regions of the colon. Anti-TfR antibodies were conjugated to nano-liposomes. As expected, iron-starved Caco-2 cells internalized anti-TfR immunoliposomes better than controls. Ex vivo binding studies to inflamed mucosa showed that the anti-TfR immunoliposomes accumulated significantly better in the mucosa of DNBS-induced rats than the accumulation of non-specific immunoliposomes. It is concluded that targeting mucosal inflammation can be accomplished by nano-liposomes decorated with anti-TfR due to inflammation-dependent, apical, elevated expression of the receptor

    HCV Causes Chronic Endoplasmic Reticulum Stress Leading to Adaptation and Interference with the Unfolded Protein Response

    Get PDF
    BACKGROUND: The endoplasmic reticulum (ER) is the cellular site for protein folding. ER stress occurs when protein folding capacity is exceeded. This stress induces a cyto-protective signaling cascades termed the unfolded protein response (UPR) aimed at restoring homeostasis. While acute ER stress is lethal, chronic sub-lethal ER stress causes cells to adapt by attenuation of UPR activation. Hepatitis C virus (HCV), a major human pathogen, was shown to cause ER stress, however it is unclear whether HCV induces chronic ER stress, and if so whether adaptation mechanisms are initiated. We wanted to characterize the kinetics of HCV-induced ER stress during infection and assess adaptation mechanisms and their significance. METHODS AND FINDINGS: The HuH7.5.1 cellular system and HCV-transgenic (HCV-Tg) mice were used to characterize HCV-induced ER stress/UPR pathway activation and adaptation. HCV induced a wave of acute ER stress peaking 2-5 days post-infection, which rapidly subsided thereafter. UPR pathways were activated including IRE1 and EIF2α phosphorylation, ATF6 cleavage and XBP-1 splicing. Downstream target genes including GADD34, ERdj4, p58ipk, ATF3 and ATF4 were upregulated. CHOP, a UPR regulated protein was activated and translocated to the nucleus. Remarkably, UPR activity did not return to baseline but remained elevated for up to 14 days post infection suggesting that chronic ER stress is induced. At this time, cells adapted to ER stress and were less responsive to further drug-induced ER stress. Similar results were obtained in HCV-Tg mice. Suppression of HCV by Interferon-α 2a treatment, restored UPR responsiveness to ER stress tolerant cells. CONCLUSIONS: Our study shows, for the first time, that HCV induces adaptation to chronic ER stress which was reversed upon viral suppression. These finding represent a novel viral mechanism to manipulate cellular response pathways

    Deletion of XBP-1 impairs MCMV infection in vivo.

    No full text
    <p>RERT XBP-1<sup>f/f</sup> mice were treated with either vehicle or tamoxifen. One week later mice were infected with a luciferase expressing MCMV. Mice were sacrificed 4 dpi and organs were extracted. (A) Liver paraffin-embedded sections were decorated with αIE1 to visualize viral foci. (B+E) viral genome copy number in mg tissue was determined using quantitative RT-PCR analysis of viral M55(gB) and the host gene pThrp in liver (B) and lung (E) (n = 3). The expression of representative viral RNA (IE1, E1 and M55(gB)) in liver (C) or lung (F) was measured by quantitative RT-PCR and calculated relative to vehicle treated animals (n = 6 (vehicle), n = 8 (tamoxifen)). Luciferase activity, representing viral protein expression was measured in liver (D) or lung (G) (n = 6 (vehicle), n = 7 (tamoxifen). Results are shown as mean ± SEM and are combined from two independent experiments. * P<0.05, ** P<0.01.</p

    Induction of XBP-1 KO in primary MEFs prior to MCMV infection decelerates viral growth and protein expression.

    No full text
    <p>Primary MEFs derived from RERT/XBP-1<sup>f/f</sup> mice were treated with vehicle (EtOH) or 4-OHT for 48 h and infected with MCMV-GFP atMO1 = 0.1 (A) and MOI = 1 (B). Culture supernatants were collected at indicated time points and titers were determined using standard plaque assay. (C) The expression of virus-derived GFP in RERT/XBP-1<sup>f/f</sup> (C) and RERT/XBP-1<sup>WT/WT</sup> (D) was monitored using flow cytometry. GFP positive cells were gated and considered as infected cells. (E, F) DNA was extracted from described cells and the genomic deletion of XBP-1 following EtOH or 4-OHT treatment was demonstrated using PCR analysis. Upper band represents deleted allele. (G) The expression of intrinsic viral proteins Immediate Early 1 (IE1), Early 1 (E1) and a 48 kDa late protein was measured by Western blot analysis. Cellular p97 served as loading control. (H) Total protein synthesis was assessed by radioactive pulse labeling and quantified using ImageJ. Data is from one experiment out of two (D, H), or three performed (C, G). (A, B) Results are shown as mean ±SEM of at least three replicates. * P<0.05, ** P<0.01.</p

    IFNβ mRNA levels are lower following MCMV infection in XBP-1 deleted cells.

    No full text
    <p>RERT/XBP-1<sup>f/f</sup> MEFs (A) and PMs (B) were treated with EtOH or 4-OHT for 48 h. Cells were then infected with MCMV at MOI = 1 and the mRNA levels of IFN-β were measured by quantitative RT-PCR at 12 hpi. Fold induction was calculated relative to expression levels in mock infected cells. (B) Results are shown as mean ±SEM of three replicates * P<0.05, ** P<0.01.</p

    Viral infection-induced deletion of XBP-1 does not affect viral RNA and protein expression in PMs.

    No full text
    <p>Primary PMs derived from XBP-1<sup>f/f</sup> mice were infected with MCMV or MCMV-CRE at MOI = 1 and the expression of intrinsic viral proteins (A) was measured by Western blot. Cellular p97 served as loading control. (B) The transcription levels of representative MCMV genes were analyzed by quantitative RT-PCR at 12 hpi and calculated relative to expression levels in mock infected cells. (A) Data is from one representative experiment out of three performed. (B) Results are shown as mean ±SEM of three replicates.</p
    corecore